Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MELASTOP

Financiado

Cerrado

Discovery of mevalonate and UBIAD1 inhibitors as novel drugs targeting melanoma...

Discovery of mevalonate and UBIAD1 inhibitors as novel drugs targeting melanoma skin cancer Melanoma is the most aggressive skin tumor, extremely difficult to treat and with high mortality rate. Overcoming reduced sensitivity and acquired resistance to targeted therapy is a major goal of current melanoma research. Theref... ver más

30/06/2024

UNIPD

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIPD

150.00K€ | Lider

SUN RACE ENGINEERING DEVELOP...

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-63638-R PROTEINAS SCAFFOLD COMO MODULADORES DE LA RESISTENCIA A INHI... 472K€ Cerrado

2MoveMate4Melanoma A treatment for BRAF inhibitor resistant melanoma 150K€ Cerrado

METABOSET Unraveling metabolic settings and targeting metabolic enzyme... 173K€ Cerrado

Bcl-Inhib Discovery of Bcl 3 inhibitors as Potential Chemopreventive A... 150K€ Cerrado

RTI2018-094629-B-I00 SUPERAR LA RESISTENCIA A MEDICAMENTOS MEDIADA POR TRIB2 EN M... 151K€ Cerrado

PDC2022-133569-I00 DESARROLLO DE UN BIOMARCADOR DE LA RESPUESTA TERAPEUTICA DEL... 150K€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2020-12-14
Fecha Fin: 2024-06-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Melanoma is the most aggressive skin tumor, extremely difficult to treat and with high mortality rate. Overcoming reduced sensitivity and acquired resistance to targeted therapy is a major goal of current melanoma research. Therefore, there is an urgent need for development of novel drugs that can cure and prolong the survival of melanoma patients. Molecular targeted therapy by using a drug that reduces the growth and spread of cancer cells via inhibition of specific protein or pathway is a milestone of precise medicine and treatment. Recent observations demonstrate that BRAF and MEK inhibitors induce increased reactive oxygen species (ROS) in melanoma and as a consequence tumor cells activate adaptive antioxidant mechanisms to keep their cellular redox state below a deadly threshold. Thus, it has been proposed that removal of antioxidant could be exploited for therapeutic benefits. In our ERC Consolidator grant RENDOX we have characterized the mevalonate metabolic pathway and discovered that this metabolic pathway as well as its enzyme, UBIAD1, have antioxidant properties and are critical caretakers of oxidative stress and ferroptosis in pathological conditions, such as melanoma progression. The MELASTOP project is grounded on the validation and repositioning of pre-existing inhibitors, such as statins and parabens derivatives (UBIAD1i) as novel therapeutic drugs to treat melanoma resistance, which represents an extraordinary opportunity to improve the current limitation. The current ERC PoC proposal aims at lead optimization, preclinical validation, IPR positioning, marker assessment and other commercial activities including go to market strategy and dialogue with potential collaborators of these mevalonate and UBIAD1 inhibitors. We envision that this PoC represents a unique medical and commercial opportunity to treat and cure BRAF-resistant melanoma patients in urgent need of new treatment options.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores